caspase-1 |
|
Vaxjo ID |
271 |
|
Vaccine Adjuvant Name |
caspase-1 |
|
Adjuvant VO ID |
VO_0005548
|
|
Description |
A protease that induces pyroptosis and cleaves pro-inflammatory cytokines IL-1β and IL-18. Engineered as a constitutively active form to enhance vaccine immunogenicity. |
|
Stage of Development |
Research |
|
Components |
active caspase-1 DNA induced pro-IL-1β maturation and IL-1β release as well as gasdermin D-dependent cell death. |
|
Structure |
Contains CARD domain, catalytic p20 and p10 subunits; engineered form lacks CARD and is auto-cleaving for constant activation. |
|
Storage |
–20 °C |
|
Preparation |
DNA plasmids encoding constitutively active caspase-1 co-injected intradermally with antigen DNA in mice |
|
Dosage |
10 µg DNA (1:1 ratio with antigen plasmid); higher/lower doses tested (2 µg and 50 µg) |
|
Function |
Active caspase-1 accelerated and amplified antigen-specific CD8 T cell responses when administered simultaneously with the DNA vaccine at an equimolar dose. |
|
Safety |
Well tolerated in mice; no local inflammation despite pyroptosis; safer than Alum (no off-target effects) |
| References |
Arakelian et al., 2022: Arakelian T, Oosterhuis K, Tondini E, Los M, Vree J, van Geldorp M, Camps M, Teunisse B, Zoutendijk I, Arens R, Zondag G, Ossendorp F, van Bergen J. Pyroptosis-inducing active caspase-1 as a genetic adjuvant in anti-cancer DNA vaccination. Vaccine. 2022; 40(13); 2087-2098. [PubMed: 35177300].
|
